Gilead strikes deal with GlobeImmune on hepatitis B vaccine

StephenW

http://www.bizjournals.com/sanfrancisco/blog/biotech/2011/10/gilead-globeimmune-hepatitis-b.html
Gilead strikes deal with GlobeImmune on hepatitis B vaccine                                                                                                                                                                                               San Francisco Business Times
by Ron Leuty, Reporter
Date: Monday, October 24, 2011, 3:37pm PDT - Last Modified: Monday, October 24, 2011, 8:18pm PDT                     

Ron LeutyReporter - San Francisco Business Times   Email                           | Twitter: @rleuty_biotech  | Twitter: @rleuty_china                          
Gilead Sciences Inc. will back GlobeImmune Inc. ’s hepatitis B vaccine program through Phase Ia trials and then take full responsibility of the program.
Foster City-based Gilead (NASDAQ:GILD) will pay privately held GlobeImmune of Louisville, Colo., an undisclosed upfront payment plus additional milestone payments and, potentially, royalties.
The goal is to use the vaccine in conjunction with Gilead’s Viread and other oral therapies to treat chronic hepatitis B infections. The companies are trying to develop specific hepatitis B DNA antigens cloned into a species of yeast.
“Finite therapy remains a significant unmet need for patients with chronic hepatitis B,” Gilead Chief Scientific Officer Norbert Bischofberger said in a press release.
Hepatitis B, which can lead to liver inflammation, vomiting and, sometimes, death, is transmitted through blood or other bodily fluids. It is particularly acute among the Asian-American community, where one in 10 people have chronic hepatitis B, which can also cause liver cancer.

Gilead公司的罢工与GlobeImmune乙肝疫苗的处理
旧金山商业时报“罗恩Leuty，记者
日期：2011年10月24日，星期一，3:37下午PDT - 上次修改时间：2011年10月24日（星期一），8:18 PM PDT
放大图片
Gilead公司的罢工与GlobeImmune乙肝疫苗的处理

罗恩Leuty
    记者 - 旧金山商业时报“
    电子邮件| Twitter的@ rleuty_biotech| Twitter的：@ rleuty_china

Gilead Sciences公司GlobeImmune公司的B型肝炎疫苗通过Ia期临床试验方案，然后采取该方案的全部责任。

福斯特城的Gilead公司（纳斯达克股票代码：GILD）科罗拉多州路易斯维尔，一个秘密的前期付款，加上额外的里程碑付款，及潜在的特许权使用费支付私人持有GlobeImmune。

我们的目标是使用结合Gilead的Viread和其他口服疗法治疗慢性乙型肝炎感染的疫苗。该公司正试图制定具体的乙肝DNA抗原克隆到一个物种的酵母。

“有限治疗，仍然是一个重大的慢性乙型肝炎患者未得到满足的需求，”Gilead公司首席科学官诺伯特Bischofberger在一份新闻稿中说。

B型肝炎，可导致肝脏发炎，呕吐，有时，死亡，是通过血液或其他体液传播。特别是急性之间的亚裔美国人社区，其中十分之一的人有慢性乙型肝炎，这也可能导致肝癌。








(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

                                                                                Gilead andGlobeImmune Inked an exclusive worldwide license and collaboration agreement centered on the development of therapeuticvaccines for use in combination with Gilead’s marketed drugViread® (tenofovir disoproxil fumarate) and other treatments for chronichepatitis B virus (HBV) infection. Gilead will pay its partner an up-front payment and provide support for GlobeImmune’s continued development of its HBV therapeutic vaccine through Phase Ia clinical trials. Gilead will then be able to take over full responsibility for further development of the vaccine, in return for additional development milestones and royalties on future sales.
GlobeImmune is focused the development of therapeutic Tarmogen vaccines for the treatment of infectious diseases and cancer. Tarmogen vaccines are whole, heat-killed recombinant Saccharomyces cerevisiae yeast cells engineered to produce one or more target disease antigens, such as viral proteins or cancer-associated proteins. The company’s lead infectious disease product candidate, GI-5005, is a Tarmogen vaccine in Phase II development for the treatment of chronic hepatitis C infection (HCV).
The collaboration with Gilead aims to generate therapeutic vaccine products that have a specific HBV DNA antigens cloned into S. cerevisiae. The firms anticipate that combining a therapeutic vaccine with oral suppressive antiviral therapy will help increase surface antigen (HBsAg) loss with seroconversion. “Based on the proof-of-concept studies in hepatitis C infection, we believe that the combination of GlobeImmune’s Tarmogen immunotherapy products with oral suppressive antiviral therapy will help eliminate the cells harboring the hepatitis B virus, thus increasing seroconversion within a finite period,” remarks David Apelian, M.D., senior vp of R&D, and CMO at GlobeImmune.
Gilead reported sales of Viread for the treatment of HIV infection and chronic HBV were $185.7 million in the second quarter of 2011, up from $176.2 million in the second quarter of 2010.